An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schizophreniform or Schizoaffective Disorders

NCT01855074 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia
Schizophreniform Disorder
Schizoaffective Disorder

Interventions

DRUG: Risperidone

Sponsor

Janssen-Cilag Ltd.